Filing Flows › 10x Genomics (TXG) › Q3 2026
10x Genomics (TXG) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
10x Genomics (TXG) reported revenue of $151M for the third quarter 2026 (Q3 2026), +1% from a year earlier and -0.2% from the quarter before. Operating margin was -10.7%, net loss $19.4M (12.9% of revenue).
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $151M | -0.2% | +1% |
| Operating profit | −$16.1M | — | — |
| Net earnings | −$19.4M | — | — |
| Operating cash flow | $15.8M | -7% | -63% |
| Free cash flow | $14.9M | -3% | -65% |
What changed
Revenue was $150.7M in Q3 2026, up 1% year over year and roughly flat from the previous quarter. Single Cell was the largest line at 62% of revenue. Spatial added $5.8M year over year (up 16%), 349% of the total change. Spatial declined 57%.
Gross margin was 75.0%, up 7.6 points from Q3 2025. Operating costs exceeded revenue by $16.1M, an operating margin of -10.7%. Operating expenses fell 3% while revenue rose 1%. The quarter ended with a net loss of $19.4M, wider than the previous quarter's $17.9M loss.
Operating cash flow was $15.8M (down 63% year over year). Non-cash charges added back $9.5M of depreciation and amortization and $23.1M of share-based compensation. Working capital and other items added $2.7M. Capital expenditures of $1.0M left free cash flow of $14.9M.
Questions
What was 10x Genomics' revenue in the third quarter 2026?
10x Genomics (TXG) reported revenue of $151M for the third quarter 2026 (Q3 2026), +1% from a year earlier and -0.2% from the quarter before.
Was 10x Genomics profitable in the third quarter 2026?
Operating loss was $16.1M (-10.7% of revenue) and net loss $19.4M.
Source: 10x Genomics 10-Q on SEC EDGAR.